Stephens R L, Goodman P, Crawford E D, Spicer C F, Lowe B A, Ahmann F R, Chapman R, Natale R B
University of Kansas Medical Center.
Invest New Drugs. 1990;8 Suppl 1:S69-71.
The Southwest Oncology Group (SWOG) studied the response rate and toxicity of menogaril (200 mg/m2 i.v. q 28 days) in patients with advanced metastatic renal cell carcinoma. During the early stage of the trial two partial responses were seen in the first 20 treated patients, and an additional 36 evaluable patients were studied. Three of 56 (5%) evaluable patients achieved partial responses. Significant white cell toxicity was observed. Mild or moderate degrees of thrombocytopenia, gastrointestinal side effects, alopecia and phlebitis occurred. No cardiac toxicity was noted. The low response rate suggests that menogaril in this dose schedule has no role in the treatment of patients with advanced metastatic renal cancer.
西南肿瘤协作组（SWOG）研究了美诺立尔（200mg/m²静脉注射，每28天一次）对晚期转移性肾细胞癌患者的缓解率和毒性。在试验早期，在前20例接受治疗的患者中观察到2例部分缓解，另外对36例可评估患者进行了研究。56例可评估患者中有3例（5%）获得部分缓解。观察到明显的白细胞毒性。出现了轻度或中度血小板减少、胃肠道副作用、脱发和静脉炎。未发现心脏毒性。低缓解率表明该剂量方案的美诺立尔对晚期转移性肾癌患者的治疗无作用。
Zotero 插件